Triggering necroptosis in cisplatin and IAP antagonistresistant ovarian carcinoma

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  McCabe, K E ^a   Bacos, K ^a   Lu, D ^a,b   Delaney, J R ^a   Axelrod, J ^a   Potter, M D ^a   Vamos, M ^c   Wong, V ^a   Cosford, N D P ^c   Xiang, R ^b   Stupack, D G ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NANKAI UNIVERSITY   (China)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE INHIBITOR; CISPLATIN; INHIBITOR OF APOPTOSIS PROTEIN ANTAGONIST; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING PROTEIN KINASE 3; RECEPTOR INTERACTING SERINE THREONINE KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BENZYLOXYCARBONYL-VALYL-ALANYL-ASPARTIC ACID; INHIBITOR OF APOPTOSIS PROTEIN; OLIGOPEPTIDE; PROTEINASE INHIBITOR; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, HUMAN; RIPK3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NECROPTOSIS; OVARIAN CANCER CELL LINE; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; AUTOCRINE EFFECT; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MUTATION; NECROSIS; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE;

INTRACISTERNAL A-PARTICLES;

APOPTOSIS; AUTOCRINE COMMUNICATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MUTATION; NECROSIS; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PHENOTYPE; PROTEASE INHIBITORS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928013139     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.448     Document Type: Article

References (24)

1. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013; 4: 2126.
2. Mullany LK, Richards JS. Minireview: animal models and mechanisms of ovarian cancer development. Endocrinology 2012; 153: 1585-1592.
3. Foley OW, Rauh-Hain JA, del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment. Oncology (Williston Park) 2013; 27: 288-294 298.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Kreuzaler P, Watson CJ. Killing a cancer: what are the alternatives? Nat Rev Cancer 2012; 12: 411-424.
6. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-124.
7. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81: 495-504.
8. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297-303.
9. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83: 1243-1252.
10. Christofferson DE, Li Y, Yuan J. Control of life-or-death decisions by RIP1 kinase. Annu Rev Physiol 2014; 76: 129-150.
11. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100-1111.
12. Cai Z, Jitkaew S, Zhao J, Chiang HC, Choksi S, Liu J et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2014; 16: 55-65.
13. Brunckhorst MK, Lerner D, Wang S, Yu Q. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther 2012; 13: 804-811.
14. Vamos M, Welsh K, Finlay D, Lee PS, Mace PD, Snipas SJ et al. Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. ACS Chem Biol 2013; 8: 725-732.
15. Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAPdependent and TNF-alpha-independent mechanism. Breast Cancer Res Treat 2013; 137: 359-371.
16. Remijsen Q, Goossens V, Grootjans S, Van den Haute C, Vanlangenakker N, Dondelinger Y et al. Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. Cell Death Dis 2014; 5: e1004.
17. Wang K, Li J, Degterev A, Hsu E, Yuan J, Yuan C. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett 2007; 17: 1455-1465.
18. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
19. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343: 1357-1360.
20. Wong WW, Vince JE, Lalaoui N, Lawlor KE, Chau D, Bankovacki A et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3- dependent manner. Blood 2014; 123: 2562-2572.
21. Gao F, Liang B, Reddy ST, Farias-Eisner R, Su X. Role of inflammation-associated microenvironment in tumorigenesis and metastasis. Curr Cancer Drug Targets 2014; 14: 30-45.
22. Rossi A, Torri V, Garassino MC, Porcu L, Galetta D. The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treat Rev 2014; 40: 485-494.
23. Arnedos M, Vielh P, Soria JC, Andre F. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 2014; 232: 274-282.
24. Lu D, Chen S, Tan X, Li N, Liu C, Li Z et al. Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy. Cancer Res 2012; 72: 3451-3456.